Netherlands' Redcare Pharmacy Q2 revenue rises; reaffirms 2026 outlook

Redcare Pharmacy NV

29/07/2026 05:40

Overview
Netherlands online pharmacy's Q2 revenue grew 20% yr/yr to EUR 853 mln
Adjusted EBITDA rose 63% to EUR 30 mln, margin improved to 3.5%
International segment delivered positive EBITDA for first time

Outlook
Redcare Pharmacy sees 2026 revenue growth between 15% and 17%
Company expects 2026 Group non-Rx revenue growth between 10% and 12%
Redcare Pharmacy guides 2026 adjusted EBITDA margin between 2.5% and 3.0%

Result Drivers
RX GERMANY MOMENTUM - Rx revenue in Germany grew 58%, supporting overall group revenue growth
CUSTOMER BASE EXPANSION - Active customer base increased by 0.5 mln during Q2 to 14.7 mln, contributing to higher sales
COST EFFICIENCY - Lower selling and distribution cost ratio due to more efficient marketing and operating leverage drove margin improvement

Company press release: ID:nEQ684ynxa

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Sales
Beat
EUR 853 mln
EUR 706 mln (2 Analysts)

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy", 3 "hold" and 1 "sell" or "strong sell"
The average consensus recommendation for the drug retailers peer group is "buy"
Wall Street's median 12-month price target for Redcare Pharmacy NV is €88.50, about 30.4% above its July 28 closing price of €67.85
The stock recently traded at 173 times the next 12-month earnings vs. a P/E of 515 three months ago

Reuters Recommended Reads
July 28 - Germany's Medios cuts 2026 EBITDA outlook on pharma supply price pressure
July 28 - Netherlands' Basic Fit H1 revenue rises on membership expansion
July 27 - Netherlands' Philips lifts annual profit, cash flow outlook after US tariff refund

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)